Advanced Search

 

Study ID Status Title Patient Level Data
FNM40181 Completed A single centre, randomised, double blind, cross over study to investigate longitudinal growth using knemometry in children with seasonal and perennial rhinitis during treatment with fluticasone propionate aqueous nasal spray (FPANS) 100mcg/day and placebo.
FNM40183 Completed A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Potential Effects of a Six-Week Course of Fluticasone Propionate Aqueous Nasal Spray (200mcg QD) on the HPA-Axis in 2 and <4 Year Old Subjects with Allergic Rhinitis.
FNM40184 Completed A Multicenter, randomized, double-blind, parallel-group study examining the effect of fluticasone propionate aqueous nasal spray 200mcg QD in subjects with sinus pain and pressure associated with nasal congestion due to allergic rhinitis
FNM40185 Completed A multicenter, randomized, double-blind, parallel group study examining the effect of fluticasone proprionate aqueous nasal spray 200mcg QD in subjects with sinus pain and pressure associated with nasal congestion due to allergic rhinitis
FNM40188 Completed An open study to evaluate the efficacy and tolerability of Flixonase ™ Aqueous Nasal Spray after switching from Rhinocort (Aqueous Nasal Spray or Turbuhaler) as a maintenance therapy for the treatment of perennial allergic rhinitis (PAR).
FNM40194 Completed A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Two-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg every day Versus Montelukast 10mg every day in Subjects ≥15 Years Old with Seasonal Allergic Rhinitis (SAR) Study Listed on ClinicalStudyDataRequest.com
FNM40195 Completed A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Two-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg every day Versus Montelukast 10mg every day in Subjects ≥15 Years Old with Seasonal Allergic Rhinitis (SAR) Study Listed on ClinicalStudyDataRequest.com
FNP30002 Completed Single-centre, randomised, double-blind study to determine the efficacy (and tolerability) of fluticasone propionate nasal drops 400mg OD and placebo in adult patients with nasal polyps or chronic sinusitis.Extensive searching has revealed that no clinical study report is available for this study.
FNP40010 Completed A single centre, randomised, double blind, parallel group study to determine the efficacy and tolerability of Fluticasone propionate nasal drops (Nasules) 400mcg bd, 400mcg od and placebo nasal drops in adult patients with bilateral polyposis. Study Listed on ClinicalStudyDataRequest.com
FNP40013 Completed A single –country, multicentre, open-label study to investigate the effect of Fluticasone Propionate nasal drops 800 mcg OD (divided between the nostrils) for 4 weeks on CT changes and the symptoms of nasal obstruction in the patients with nasal polyposis in preoperative period (Functional Endos ...
FNP40014 Completed A multi-centre, randomised, double-blind, parallel group study, to evaluate the efficacy and tolerability of fluticasone propionate nasal drops (Flixonase Nasule) 400 mcg twice daily and placebo in adult patients with nasal polyposis indicated for functional endoscopic sinus surgery (FESS) for a ...
FNS30003 Completed Multicentre, Randomised, Double-blind, parallel group study to evaluate the efficacy of fluticasone propionate aqueous nasal spray associated with antibiotic therapy in the treatment of patients with acute rhino-sinusitis.
FPD40001 Completed A Comparison of fluticasone propionate (250µg bid) therapy via the new Diskus® dry powder inhaler to standard therapy (usual inhaled steroid via an alternate dry powder inhaler) in patients with moderate asthma.
FPD40009 Completed A Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate Inhalation Powder (250mcg QD) and Placebo in Subjects at Least 12 Years of Age with Chronic Asthma Currently Receiving Short Acting Beta Agonist Alone Study Listed on ClinicalStudyDataRequest.com
FPD40010 Completed A Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate Inhalation Powder (250mcg QD) and Placebo in Subjects at Least 12 Years of Age with Chronic Asthma Currently Treated with Inhaled Corticosteroids Study Listed on ClinicalStudyDataRequest.com
FPD40012 Completed A Randomized, Double-Blind, Double-Dummy, Parallel Group Comparison of Fluticasone Propionate Inhalation Powder (50mcg BID) with Oral Montelukast (5mg QD) in Children 6-12 Years of Age with Persistant Asthma Study Listed on ClinicalStudyDataRequest.com
FPD40013 Completed A Randomized, Double-Blind, Double-Dummy, Parallel Group Comparison of Fluticasone Proprionate Inhalation Powder (50mcg BID) with Oral Montelukast (5mg QD) in Children 6-12 with Persistant Asthma Study Listed on ClinicalStudyDataRequest.com
FPD40014 Completed A Randomized, Double-Blind 12-Week Comparative Trial of Fluticasone Propionate DISKUS 100mcg BID Versus Fluticasone Propionate DISKUS 100mcg BID And Oral Montelukast 10mg QD In Adults With Persistent Asthma. Study Listed on ClinicalStudyDataRequest.com
FPD40015 Completed A Randomized, Open-Label, Cross Over Trial, Assessing Ease of Use, Correctness of Use and Patient Preference of Fluticasone Propionate Inhalation Powder (100mcg BID) via the Diskus versus Fluticasone Propionate Aerosol via the Metered Dose Inhaler (88mcg BID) in Subjects at Least 12 Years of Age with Persistent Asthma Currently Receiving Short Acting Beta Agonists Alone Study Listed on ClinicalStudyDataRequest.com
FPD40016 Completed A Randomized, Open-Label, Cross Over Trial, Assessing Ease of use, Correctness of use and Patient Preference of Fluticasone Propionate Inhalation Powder (100mcg BID) via the DISKUS™ versus Fluticasone Propionate Aerosol via the Metered Dose Inhaler (88mcg BID) in Subjects at Least 12 Years of Age with Persistent Asthma Currently Receiving Short Acting Beta Agonists Alone. Study Listed on ClinicalStudyDataRequest.com
FPR10001 Completed A double blind, placebo controlled, single dose, crossover study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled reformulated FP (TIBAC) in comparison with the standard formulation FP. Study Listed on ClinicalStudyDataRequest.com
FPR10006 Completed A randomised, double blind, placebo controlled, cross over study to investigate the duration of action of inhaled doses of Fluticasone Propionate (1000mg) on airway responsiveness to adenosine-5'-monophosphate (AMP) in mild asthmatic patients Study Listed on ClinicalStudyDataRequest.com
FRX106365 Completed A randomized, controlled trial to evaluate the effects of nadroparin on survival and disease progression in patients with advanced malignancies of the lung, pancreas, or prostate Study Listed on ClinicalStudyDataRequest.com
FS12004 Completed Seretide efficacy and safety monitoring in Slovenia
G91-003 Completed A Pilot Study to Investigate Morning Plasma Cortisol Levels and Plasma FP Levels Following Single Doses of FP Administered by Nebuliser (0.2%, 2x0.2% and 0.4%) and Pressurized Inhaler (2mg)

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.